1 Mitochondrial dysfunction including decrease of mitochondrial membrane potential and reduced ATP production represents a common final pathway of many conditions associated with oxidative stress, for example, hypoxia, hypoglycemia, and aging. 2 Since the cognition-improving effects of the standard nootropic piracetam are usually more pronounced under such pathological conditions and young healthy animals usually benefit little by piracetam, the effect of piracetam on mitochondrial dysfunction following oxidative stress was investigated using PC12 cells and dissociated brain cells of animals treated with piracetam.
Introduction
Piracetam, the prototype of the so-called 'nootropic' drugs (Giurgea, 1982) , is used in many countries to treat cognitive impairment in aging, brain injuries, as well as dementia (Croisile et al., 1993; Waegemans et al., 2002) . Although its clinical efficacy is still a matter of dispute, a recent metaanalysis of all available (published and not published) clinical studies provided compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment (Waegemans et al., 2002) .
Similar to the situation in man, piracetam has also been shown to improve cognitive function in animals, but its mode of action is not yet been finally known (Giurgea, 1982; Muller et al., 1999) . Findings that piracetam's efficacy is usually associated with conditions of disturbed brain function like aging, that is, young healthy animals usually benefit little or nothing from piracetam treatment (Valzelli et al., 1980; Muller et al., 1997) , has led to the speculation that piracetam's mechanism of action is associated with biochemical deficits of the aged brain. This assumption was later supported by observations that piracetam specifically enhances membrane fluidity in aged brain material, showing no effect at all in membranes from young brains (Muller et al., 1997) . Since piracetam's effects at the membrane level were observed at concentrations also needed in pharmacological experiments to improve cognition (Muller et al., 1997) , we proposed that by restoring age-related membrane alterations piracetam improves brain function and finally cognition (Scheuer et al., 1999) . At the subcellular level, piracetam's effects on membrane fluidity could be demonstrated for synaptosomal plasma membranes of aged mouse brains and also for mitochondrial membranes .
Piracetam's improving effects on the fluidity of aged synaptosomal membranes could easily explain the beneficial effects of piracetam on age-related deficits of several mechanisms of signal transduction (receptor density and function, transmitter release) (Stoll et al., 1992; Muller et al., 1999) , since these mechanisms are disturbed in the aging brain probably due to a decrease of membrane fluidity. Piracetam's recently reported effects on impaired glucose uptake might also be a consequence of its effects on membrane fluidity (Naftalin et al., 2004) . On the other hand, evidences that piracetam's beneficial effects on the fluidity of aged mitochondrial membranes might contribute to its therapeutic efficacy are rather indirect and orginate from observations that piracetam might improve glucose uptake and utilization as well as ATP production (Domanska-Janik & Zaleska, 1977; Benzi et al., 1985; Heiss et al., 1988) . Even if these effects led to the term 'metabolic enhancer', sometimes used to characterise piracetam and related nootropics, the mechanism of this effect and its possible relationship to mitochondrial function remained obscure.
As already mentioned, piracetam's beneficial effects are usually associated with impaired brain function such as aging, hypoxia, glucose deprivation, injuries, or neurodegeneration (Giurgea, 1982; Muller et al., 1999) . It is quite remarkable that all those situations, even if other deficits are also present, are associated with mitochondrial dysfunction. Accordingly, together with our initial observations of improved mitochondrial membrane properties by piracetam, we speculated that piracetam might enhance mitochondrial function or at least protect mitochondria in situations of enhanced damage. Using specific fluorescence dyes to monitor mitochondrial membrane potential but also using other means to characterize mitochondrial function, the present communication reports a series of in vitro and in vivo experiments strongly indicating improvements of mitochondrial function as a specific property of piracetam.
Methods

Chemicals
Rhodamine 123 (R123) and tetramethylrhodamineethylester (TMRE) were purchased from Invitrogen, Karlsruhe (Germany). ViaLight HT kit was purchased from Cambrex, Verviers (Brussels). Hydrogen peroxide (H 2 O 2 ), sodium nitroprusside (SNP), rotenone, thenoyltrifluoroacetone (TTFA), antimycine, sodium azide (NaN 3 ), and oligomycine were obtained from Sigma, Munich (Germany). Piracetam was a gift from UCB (Brussels).
Cell culture
PC12 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum and 5% heat-inactivated horse serum, 50 U ml À1 penicillin, 50 mg ml À1 streptomycin, and 400 mg ml À1 G418 at 371C in a humidified incubator containing 5% CO 2 .
Animal brain tissue
Young (2-3 months) and old (22-24 months) female Naval Medical Research Institute (NMRI) mice used in this study were from Harlan-Winkelmann GmbH (Borchen, Germany). The latter were obtained at an age of 12 months and maintained at the Biocenter's animal care facility until use. All animals were housed in plastic cages with water and food ad libitum and were maintained on a 12-h light/dark cycle. Animals were handled according to the German guidelines for animal care.
Mice were killed by decapitation and brains were quickly dissected on ice (method modified after Stoll et al., 1992) . After removing the cerebellum, the tissue was minced into 2 ml of medium I (NaCl 138, KCl 5.4, Na 2 HPO 4 0.17, K 2 PO 4 0.22, glucose 5.5 and sucrose 58.4 all in mmol l À1 , pH 7.35) with a scalpel and further dissociated by trituration through a nylon mesh (pore diameter 1 mm) with a pasteur pipette. The resulting suspension was filtered by gravity through a fresh nylon mesh with a pore diameter of 102 mM and the dissociated cell aggregates were washed twice with medium II (NaCl 110, KCl 5.3, CaCl 2 . H 2 O 1.8, MgCl 2 . 6 H 2 O 1, glucose 25, sucrose 70, and HEPES (4-2-hydroxyethyl)-1-piperazineethanesufonic acid) 20 all in mmol l À1 , pH 7.4) by centrifugation (400 Â g for 3 min at 41C). In all, 100 ml of the suspension was used for protein determination. After centrifugation, cells were resuspended in 6 ml DMEM and distributed on a 48 well plate for the measurement of mitochondrial membrane potential. The data were expressed as fluoroscence unit per mg ml À1 protein.
Measurement of mitochondrial membrane potential
PC12 cells were plated the day before at a density of 2 Â 10 5 cells well À1 in a 24-well plate. The mitochondrial membrane potential was measured using the fluorescence dye R123 (Baracca et al., 2003) . Transmembrane distribution of the dye depends on the mitochondrial membrane potential. The dye was added to the cell culture medium at a concentration of 0.4 mM for 15 min. The cells were washed twice with Hanks' balanced salt solution and the fluorescence was determined with a fluorescence reader (Victor s multilabel counter) at 490/535 nm.
The mitochondrial membrane potential of dissociated brain cells was also measured with R123 at a concentration of 0.4 mM for 15 min. For detailed information about the preparation, see under Animal brain tissue.
To test acute and fast changes in mitochondrial membrane potential, the fluorescence dye TMRE (Collins et al., 2002) was used at a concentration of 0.4 mM for 15 min. TMRE exhibits a characteristic increase in fluorescence at 490/590 nm after challenging mitochondria with membrane potentialdecreasing drugs (Krohn et al., 1999) . The mitochondrial membrane potential was recorded and then the complex inhibitors (rotenone 2 mM, TTFA 10 mM, antimycine 2 mM, oligomycine 10 mM, and NaN 3 10 mM) were added.
Determination of ATP levels with a bioluminescence assay (ViaLightt HT) PC12 cells were plated the day before at a density of 2 Â 10 4 cells well À1 in a white 96-well plate. The kit is based upon the bioluminescent measurement of ATP (Crouch et al., 1993) . The bioluminescent method utilizes an enzyme, luciferase, which catalyzes the formation of light from ATP and luciferin. The emitted light is linearly related to the ATP concentration and is measured using a luminometer.
Piracetam treatment
PC12 cells were treated in three different ways. First, the protective effect of piracetam on recovery after oxidative stress was tested. Thus, PC12 cells were treated for 24 h with SNP (0.5 mM), piracetam was added 30 min after the onset of SNP exposure. Second, PC12 cells were pretreated for 30 min with SNP, then the medium was exchanged and piracetam was added for 23 h. Third, PC12 cells were pretreated for 6 h with piracetam, after that the mitochondrial membrane potential was recorded, and then the complex inhibitors were added. Dissociated brain cells were treated for 6 h with SNP (2 mM), and piracetam was added 1 h after the onset of SNP exposure.
Treatment of animals
The treated animals received 100, 250, or 500 mg kg À1 piracetam in 0.9% NaCl solution p.o. once daily for 2 weeks. Control animals were treated with 0.9% NaCl alone. The tests were implemented 24 h after the last feeding. The dissociated brain cells of untreated and treated mice were incubated for 4 or 6 h with H 2 O 2 (2 mM) or SNP (2 mM).
Measurement of caspase 9 activity
PC12 cells were plated the day before at a density of 5 Â 10 6 cells per culture dish (10 cm diameter). After pretreatment for 22 h with piracetam, SNP was added for 2 h. The cells were harvested, and, after a centrifugation step, the culture medium was aspirated. The cell-containing pellet was washed with PBS and lysed in 100 ml of lysis buffer (10 mM HEPES, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM EDTA, 1 mM dithiothreitol, 1 mg ml À1 pepstatin A, 1 mg ml À1 leupeptin, 0.1% CHAPS, pH 7.4). Lysates were centrifuged at 20,000 Â g for 10 min at 41C, and the supernatant was used for caspase assay. Caspase 9 activity was measured by cleavage of the colorimetric substrate Ac-LEHD-pNA for caspase 9. The production of pNA was monitored over 30 min in a photometer at 405 nm. The caspase activity is expressed as change in absorption units. One unit was defined as the amount of enzyme required to cleave 1 pmol of NA per min of incubation per 5 Â 10 6 cells. For details, see Marques et al. (2003) .
Cu/Zn-superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) activity assays
For determination of antioxidative enzyme activities, we prepared frozen brain hemispheres. Tissue samples without cerebellum were washed in 1 ml EDTA and 1 ml Tris buffer (20 mM, pH 7.4) and homogenized with a Potter homogenizer in 20 mM Tris buffer. The resulting homogenates were centrifuged at 8500 Â g for 10 min at 41C. The clear supernatants were used to determine the activity of SOD, GPx and GR according to Leutner et al. (2001) and Schuessel et al. (2004) .
SOD activity
The assay of Cu/Zn-SOD is based on the method of Nebot et al. (1993) , utilizing the commercially available SOD Assay Kit from Merck Biosciences, Bad Soden (Germany).
For elimination of interfering substances and Mn-SOD activity, Cu/Zn-SOD enzyme activity was assayed after the extraction procedure with chloroform and ethanol according to the supplier's manual. SOD activity was determined from the V s /V c ratio of the autoxidation rates of the chromophore BXT-01050 at 371C measured in the presence (V s ) and absence (V c ) of sample. One SOD activity unit is defined as the activity that doubles the autoxidation background (V s /V c ¼ 2).
GPx activity
The assay of GPx (cytosolic GPx) is based on the reaction described by Paglia & Valentine (1967) using the commercially available Cellular GPx Assay Kit from Merck Biosciences, Bad Soden (Germany). Tert-butylhydroperoxide was used as substrate.
One unit of GPx is defined as the activity that converts 1 mmol of reduced glutathione per litre per minute at 251C.
GR activity
The GR-activity assay is based on the method of Mizuno & Ohta (1986) . Enzymatic activity was assayed photometrically by measuring NADPH consumption during the enzymatic reaction: in the presence of GSSG and NADPH, GR reduces GSSG and oxidizes NADPH to yield NADP, resulting in a decrease of absorbance at 340 nm. We used the commercially available GR Assay Kit from Merck Biosciences, Bad Soden (Germany).
One unit of GR is defined as the activity that converts 1 mmol of NADPH per litre per minute at 251C.
Statistics
Data are given as mean7s.e.m. n is the number of independent experiments usually performed in triplicates. In animal studies it is the number of animals. For statistical comparison, Student's t-test, one-way ANOVA followed by Tukeys post hoc test or repeated-measures ANOVA followed by Tukeys post hoc test were used. P-values less than 0.05 were considered statistically significant.
Results
Protection against NO-induced oxidative stress in PC12 cells
Oxidative stress accumulates with aging and plays an important role in the pathogenesis of neurodegenerative disorders including Alzheimer's disease (AD) (Butterfield et al., 1999; Christen, 2000; Wei & Lee, 2002; Sastre et al., 2003; Emerit et al., 2004) . For our initial experiments using PC12 cells in tissue culture, we experimentally induced acute oxidative stress using different approaches to mirror acutely damages, which are usually seen in the aged brain only after years Keil et al., 2004) .
Nitric oxide (NO) and its derivative peroxynitrite radical induce oxidative stress. NO inhibits cytochrome c oxidase activity (Brunori et al., 1999; Sarti et al., 2000; Cooper, 2002) . Inhibition of mitochondrial respiratory chain by NO may
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Piracetam protects mitochondria cause apoptosis (Brown & Borutaite, 2002; Vieira & Kroemer, 2003) . In PC12 cells, SNP, a NO donor, led to a reduction of mitochondrial membrane potential and ATP levels ( Figure 1 ). Under basal conditions without additional damage, piracetam did not affect mitochondrial membrane potential and ATP levels in PC12 cells even after 24 h incubation and at rather high concentrations (data not shown). However, piracetam was able to reduce mitochondrial membrane potential changes and to enhance ATP levels, when added 30 min after the onset of SNP exposure (Figure 1a) . Additionally, piracetam improved the recovery of mitochondrial membrane potential and ATP levels after exchanging the medium following SNP exposure (Figure 1b) .
Protection against mitochondrial damage due to reduction of neurotrophic support in PC12 cells
Cells require serum to maintain growth in vitro. Serum provides growth and survival factors and its removal causes cellular stress. Serum deprivation leads to a rise of ROS and a decrease of ATP levels in neurons (Atabay et al., 1996) .
Additionally, serum and glucose deprivation in PC12 cells cause peroxidation of their cell membrane lipids and decrease intracellular SOD activity (Ochiai et al., 2004) . We have previously shown that serum deprivation enhances apoptosis in PC12 cells (Leutz et al., 2002) . Here, we could demonstrate that serum deprivation leads to a decrease of mitochondrial membrane potential (Figure 2a ). Interestingly, piracetam was able to protect mitochondria against cellular stress following serum deprivation. The decrease of mitochondrial membrane potential after serum deprivation was significantly reduced (Figure 2a) .
Under conditions of mild serum deprivation, when serum concentrations not lower than 2% were used, piracetam (500 mM) induced a nearly complete recovery of mitochondrial membrane potential (Figure 2b ). ATP levels are more sensitive to serum deprivation (Figure 2c ). Reduced ATP levels were already seen at 10% serum. Under this condition, piracetam completely restored ATP levels, while at lower serum concentrations only a partial restoration was seen.
Piracetam protects PC12 cells against damage induced by inhibitors of the respiratory chain
Biochemical analysis of CNS tissue from patients with AD has yielded evidence for abnormalities of components of the electron transport chain (Parker Jr et al., 1994b) . In many AD patients, cytochrome c oxidase activity is impaired in the CNS (Kish et al., 1992) and even in other tissues, including platelets (Parker Jr et al., 1994a; Bosetti et al., 2002; Cardoso et al., 2004) . Thus, we investigated the possible efficacy of piracetam to protect individual complexes of the mitochondrial respiratory chain after treatment with different respiratory chain complex inhibitors. Complexes I, II, and III were protected at concentrations as low as 500 mM piracetam ( Figure 3 , Table 1 ). A significant protection of complexes IV and V was observed at a concentration of 1000 mM piracetam (Table 1) .
Other antidementiva and antipsychotic drugs had no effect on mitochondrial membrane potential and ATP levels
We investigated the putative protective effects of other antidementiva and psychotropic drugs like memantine, galantamine, haloperidol, imipramine, fluoxetine, or trolox on mitochondrial function by measuring mitochondrial membrane potential and ATP levels under similar conditions. PC12 cells were incubated with SNP for 24 h, 30 min after insult the drugs were added. Interestingly, none of the investigated drugs was able to diminish the decrease of mitochondrial membrane potential and the reduction of ATP levels (Figure 4a and b) . Thus, the protective effect of piracetam under similar conditions shows a substantial specificity.
Piracetam reduces caspase 9 activity after SNP exposure Caspase 9 represents the last specific step of the intrinsic pathway of apoptosis, which is triggered from mitochondria following oxidative stress (Kroemer & Reed, 2000) . The activation of caspase 9 leads to activation of the executor caspase 3, which is common also for the extrinsic apoptotic pathway, and finally leads to apoptotic cell death. Caspase 9 is activated in PC12 cells after SNP exposure with a maximum (Figure 6a ). This effect was already seen at the rather low piracetam concentration of 500 mM.
Piracetam normalizes the basal level of mitochondrial membrane potential in vivo
Brain cells of aged mice show a decreased mitochondrial membrane potential compared to young mice (Figure 6c ). Contrary to our in vitro data, piracetam treatment of young (Figure 6d ). The protection in aged mice was always more pronounced than in young animals. Therefore, the dose dependence of piracetam's protective effects was investigated in aged mice only. Consistent with our first study, piracetam normalized basal levels of mitochondrial membrane potential and protected against H 2 O 2 -and SNP-induced mitochondrial dysfunction, with first effects already seen at concentrations of 250 mg kg À1 (Figure 7a-c) .
Effects of aging and treatment with piracetam on antioxidative enzyme activities in the mouse brain
Antioxidative enzymes are the primary defense mechanism to protect biological macromolecules from oxidative damage, and are upregulated in aged mouse brain as an adaptive response to oxidative stress (Leutner et al., 2001; Schuessel et al., 2005) . Therefore, we investigated the effect of piracetam treatment on the activities of SOD, GPx, and GR in young mice (2-3 months old) and old mice (22-24 months old).
We confirmed a significant increase in GPx and GR activity in aged mice compared to young mice (Figure 8b and c) . The activity of SOD had also a tendency to increase with age ( Figure 8a ). Piracetam treatment decreased the activities of all three enzymes in aged mice nearly to the level of young animals (Figure 8a-c) . In young mice, a only small and not significant decrease of antioxidative enzymes could be observed (Figure 8 ).
Discussion
The data presented clearly show that piracetam protects mitochondria against different conditions associated with oxidative stress including aging. Piracetam's protecting effects on mitochondrial damage induced in vitro are small, but reproducible and highly significant. This is not surprising, since the conditions used to induce oxidative stress in vitro are not physiological and rather massive, in contrast to the small and slowly occurring changes induced by aging, which however were sometimes completely reversed by piracetam treatment. This was also the case for the adaptive elevation of antioxidant enzyme activities. When mild conditions were uesd in vitro (e.g. partial serum deprivation), a complete protection of mitochondria was seen by piracetam treatment in PC12 cells. Moreover, piracetam was highly effective in vivo in pathophysiologically relevant situations of brain dysfunction.
Piracetam does not possess radical scavenging properties (Bentue-Ferrer et al., 1989; Horvath et al., 2002) . This observation was recently confirmed by us since piracetam up 
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Piracetam protects mitochondria to 5 mM had no activity at all in two typical in vitro antioxidant assays (guajacol and oxyhemoglobin assay) (unpublished observations). Moreover, the classical radical scavenger trolox was not able to protect mitochondria under similar conditions (Figure 4 ). Thus, it seems quite likely that piracetam acts directly at the mitochondrial level, presumably by improving mitochondrial membrane properties . This is also supported by our observation that the protective effects were also seen in the recovery phase, when the oxidative stressor was already removed. Moreover, initial experiments from our lab also indicate similar effects of piracetam on isolated mouse brain mitochondria of animals treated with piracetam (unpublished observations). The concentrations of piracetam effective in vitro (100-1000 mM) and the doses used in the in vivo experiments (100-500 mg kg À1 ) are quite well within the plasma concentrations seen in patients treated with the standard dose of about 5 g daily, which range between 200 and 2000 mM (Saletu et al., 1986; . Thus, it is quite likely that similar effects are also taking place in the brain of piracetam treated patients (Heiss et al., 1988; Eckert et al., 1999) .
At such therapeutically relevant concentrations, piracetam seems to interact rather unspecifically with the polar head groups of the lipid bilayer of cellular membranes (Peuvot et al., 1995; Muller et al., 1997) . Its structural analogue aniracetam binds to specific recognition sites associated with AMPAsensitive glutamate receptors (Fallarino et al., 1995; O'Neill et al., 2004) . However, piracetam does not interact with these sites up to 2 mM (Fallarino et al., 1995) .
While the interaction of piracetam with membranes shows little further changes of membrane properties under normal conditions, it significantly enhances reduced membrane fluidity, for example, in the aging or even Alzheimer brain (Muller et al., 1997; Eckert et al., 1999) . All the conditions 
Piracetam protects mitochondria associated with positive effects of piracetam on mitochondrial function in the present report may also be associated with decreased membrane fluidity due to enhanced lipid peroxidation and other damages. Thus, it seems quite plausible that piracetam improves mitochondrial function by enhancing membrane fluidity. However, direct proof for this mechanism still needs to be given. Piracetam also improved mitochondrial membrane potential after stimulation with several inhibitors of the mitochondrial respiratory chain, where complexes I, II, and III were specifically sensitive. Since the complexes are located in the inner mitochondrial membrane, this structure might benefit specifically by piracetam. Impaired mitochondrial function and decreased activity of the respiratory chain will lead to reduced ATP levels, decreased glucose uptake, and finally to neuronal dysfunction, situations which all can be improved by piracetam (Benzi et al., 1985; Saletu et al., 1986; Heiss et al., 1988; Szelies et al., 2001) . Impaired mitochondrial function will finally also lead to activation of caspases and apoptotic cell death. Observations with piracetam of Gabryel et al. (2002) , about improved MTT reduction and enhanced ATP levels in astrozytes after hypoxia and reoxygenation, and by Pelsman et al. (2003) , about reduced apoptosis after H 2 O 2 treatment of human cortical neurons, together with our observation of reduced caspase 9 activity following oxidative stress, fit perfectly into the findings of a direct mitochondrial stabilization by piracetam. This might lead to improved respiratory chain function and ATP production on the one hand and reduced apoptosis signalling on the other hand.
Piracetam also markedly protects against mitochondrial dysfunction induced by serum deprivation and even seems to enhance or normalize mitochondrial function in situations of mildly reduced trophic support.
Serum deprivation leads to a decrease of cellular ATP/ADP ratio (Gottlieb et al., 2002) and to an energy deficiency. Piracetam is known to enhance cerebral glucose metabolism (Heiss et al., 1988) . Moreover, Piracetam antagonizes inhibition of human erythrocyte D-glucose transport by barbiturates, diazepam, melatonin, and galanin (Naftalin et al., 2004) . Thus, enhanced glucose transport in the cells might contribute to the stabilization of mitochondrial function during serum deprivation. In addition, serum deprivation induces opening of the permeability transition pore (Furuno et al., 2001) . Due to the membrane-stabilizing properties, piracetam might inhibit the opening of the permeability transition pore and so protect mitochondria under serum-deprivated conditions. Furthermore, piracetam has been shown to be specifically active in preventing hypoxia-induced sensitization of animals for convulsive drugs (Rauca et al., 2000) . Interestingly, this kindling-like phenomenon has been associated with reduced levels of trophic factors. The assumption that piracetam also compensates for cellular (mitochondrial) dysfunction associated with reduced neurotrophic support and might even improve neurotrophic mechanisms could be an explanation that piracetam might enhance the restitution and reorganization of neuronal circuits after periods of brain damage in experimental animals or patients following stroke (Coq & Xerri, 1999; Szelies et al., 2001) .
In summary, protection against mitochondrial dysfunction, improved ATP production, and prevention of apoptotic signals may be important features of piracetam's beneficial effects in aging and neurodegeneration. Since mitochondrial dysfunction and reduced energy metabolism seem to be very early events during the course of AD (Mielke et al., 1994; Santens et al., 2001; Eckert et al., 2003; Keil et al., 2004) , the present findings can easily explain piracetam's beneficial effects on glucose utilization in AD patients (Domanska-Janik & Zaleska, 1977; Benzi et al., 1985; Heiss et al., 1988) together with its effects on glucose uptake. This study was supported by UCB, Belgium.
